ABBOTT LABORATORIES
ABTNYSE🏆 #66 by market capUS Equity
$109.75▲ $1.09 (+0.99%)
Live1h—
24h▲ 1.0%
7d▲ 3.9%
14d▲ 1.5%
30d▲ 19.1%
1y▼ 16.3%
🏦Market Cap
$189.90B
Mid Cap
📈Revenue Growth (YoY)
+8.1%
Slowing
📊Gross Margin
56.8%
Healthy
💵FCF Margin
15.8%
Healthy
⚖️P/S Ratio
4.0x
Fair
Otter Score
69
Fair
Trading Snapshot
- Day Range
- $108.57 – $111.39
- 52-Week Range
- $81.97 – $137.49
- Volume
- $8.84B
- Avg Volume
- $6.30B
- Shares Outstanding
- 1.73B
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $46.53B
- Last Q Revenue
- $12.77B
- P/E Ratio
- 34.7
- P/S Ratio
- 4.0x
- EPS (TTM)
- $3.11
- Dividend Yield
- 2.23%
Why Investors Own ABT
- ✓High-growth profile — revenue up +1.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$46.53B▼ −1.3% YoY
Gross Margin (TTM)
67.2%▲ +3.6% YoY
Operating Income (TTM)
$8.38B▼ −1.3% YoY
Free Cash Flow (TTM)
$8.84B▼ −1.3% YoY
About ABBOTT LABORATORIES
A company profile for ABBOTT LABORATORIES isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
69/100
Analyst Price Target
ⓘAverage Target
$131.20
▲ +19.6% Upside
High Target$161.92
Low Target$120.13
Based on 26 analysts
Latest News & Updates
🚀
Barron’s·2h ago
ABBOTT LABORATORIES tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift ABT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
ABBOTT LABORATORIES announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.